Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University Innsbruck
About this trial
The aim of the study is to develop a standardized, risk-adapted screening protocol for detecting pleuropulmonary manifestations in patients with rheumatoid arthritis. To assess the risk of these manifestations, a comprehensive range of functional and clinical evaluations will be performed and correlated with structural lung assessments using computed tomography (CT).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients ≥18 years diagnosed with rheumatoid arthritis according to current ACR/EULAR criteria
Residence in Austria
Signed and dated consent of the patient in accordance with ICH-GCP guidelines
Disqualifiers
pregnancy
age below 18 years
Contraindications to study-related routine examinations (e.g., inability to draw blood due to needle phobia, no CT scan possible due to claustrophobia, pregnancy, etc.)
Trial population
Patients aged 18 years or older, currently residing in Austria, diagnosed with rheumatoid arthritis according to the current ACR/EULAR criteria, will be eligible for study entry.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Number of RA patients with pleuropulmonary involvement according to an AI-supported multiparametric risk profile analysis
AI-supported risk factor-based analysis of pleuropulmonary involvement in RA patients assessed at a single time-point (baseline assessment). A multiparametric AI-supported evaluation based on clinical, sonographic, pulmonary function, laboratory, and exercise performance tests defines an RA population at high risk for the presence of pleuropulmonary involvement.
Time frame
single point (baseline)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov